Evidence map›Paper›PMID 41736774›Full record

ArticleKidney international reports2026

Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.

Felicitas E Hengel, Asma Beldi-Ferchiou, Hamza Sakhi, Nastassia Liaukouskaya, Silke Dehde, Alexandre Karras, Emmanuel Esteve, Julie Oniszczuk, Sabine Le Gouvello, Luis Herrera-Marcos and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Felicitas E HengelIII Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Asma Beldi-FerchiouInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Hamza SakhiInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Nastassia LiaukouskayaIII Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Silke DehdeIII Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alexandre KarrasNephrology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris Cité University, Paris, France.
Emmanuel EsteveNephrology Department, Assistance Publique-Hôpitaux de Paris, Tenon Hospital, Sorbonne University, INSERM U1115 CORAKID, Paris, France.
Julie OniszczukInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Sabine Le GouvelloInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Luis Herrera-MarcosInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Nizar JoherInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Eric DaugasNephrology Department, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris Cité University, INSERM U1149, Paris, France.
Mohamad ZaidanNephrology Department, Assistance Publique-Hôpitaux de Paris, Kremlin Bicêtre Hospital, Saclay University, Paris, France.
Khalil El KarouiNephrology Department, Assistance Publique-Hôpitaux de Paris, Tenon Hospital, Sorbonne University, INSERM U1115 CORAKID, Paris, France.
Bertrand KnebelmannNephrology Department, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris Cité University, Paris, France.
Myriam DaoNephrology Department, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris Cité University, Paris, France.
Anissa MoktefiInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Dil SahaliInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Tobias B HuberIII Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mario OlleroInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.
Nicola M TomasIII Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Vincent AudardInstitut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale, Universite Paris Est Créteil, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The identification of autoantibodies against nephrin, a key signaling protein of the podocyte slit diaphragm, and their pathogenic role in patients with minimal change disease (MCD) has substantially changed our understanding of primary podocytopathies. However, details on underlying immune pathophysiological mechanisms such as the relation of anti-nephrin autoantibodies with immune cell subsets and therapy response remain to be determined. Methods: In this prospective study, we evaluated blood samples from adults with newly diagnosed, biopsy-proven MCD for circulating anti-nephrin antibodies using immunoprecipitation (IP) and B-cell subpopulations by fluorescence-activated cell sorting. Samples were collected at diagnosis (t Results: We detected anti-nephrin antibodies in 12 of 17 (70.6%) therapy-naïve patients with MCD at t Conclusion: Our study shows, for the first time, a therapeutically relevant short-term effect of steroids on the B-cell compartment and anti-nephrin antibody levels, explaining the high clinical response rate in patients with anti-nephrin-associated MCD.

Indexed as

anti-nephrin antibodiesminimal change diseasenephrotic syndromeplasmablastssteroids

Identifiers

PMID41736774
PMCPMC12926970

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.